[go: up one dir, main page]

PE20030304A1 - Composicion cristalina que contiene escitalopram - Google Patents

Composicion cristalina que contiene escitalopram

Info

Publication number
PE20030304A1
PE20030304A1 PE2002000675A PE2002000675A PE20030304A1 PE 20030304 A1 PE20030304 A1 PE 20030304A1 PE 2002000675 A PE2002000675 A PE 2002000675A PE 2002000675 A PE2002000675 A PE 2002000675A PE 20030304 A1 PE20030304 A1 PE 20030304A1
Authority
PE
Peru
Prior art keywords
temperature
oxalate
scitalopram
solvent
cooling
Prior art date
Application number
PE2002000675A
Other languages
English (en)
Inventor
Troels Volsgaard Christensen
Ken Liljegren
Lene Andresen
Sebastian P Assenza
Shashank Mahashabde
Michiel Onne Elema
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030304(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of PE20030304A1 publication Critical patent/PE20030304A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

SE REFIERE A PREPARACIONES CRISTALINAS DE OXALATO DE ESCITALOPRAM (OXALATO DE (S)-1-[3-(DIMETILAMINO)PROPIL]-2-(4-FLUORFENIL)-1,3-DIHIDRO-5-ISOBENZOFURANOCARBONITRILO) QUE SE CARACTERIZAN POR: TAMANO GRANDE DE PARTICULAS DE 40µm O DE 50µm A 200µm, NO CONTENER LIGANTE, SIENDO UNA DOSIFICACION SOLIDA EXENTA DE LACTOSA QUE SE PRESENTA EN FORMA DE TABLETA RECUBIERTA PREPARADA POR COMPRENSION DIRECTA, CAPSULA DE GELATINA DURA, QUE CONTIENE DE 1% A 30% EN PESO DE BASE DE ESCITALOPRAM, CELULOSA MICROCRISTALINA, LUBRICANTE COMO ESTEARATO DE MAGNESIO (0,4% A 2%). TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA PREPARAR PARTICULAS CRISTALINAS DEL COMPUESTO QUE COMPRENDE: ENFRIAR EN FORMA GRADUAL UNA SOLUCION DE OXALATO DE ESCITALOPRAM EN UN SISTEMA DE SOLVENTES (ETANOL, AGUA) DESDE UNA PRIMERA TEMPERATURA (ENTRE 50°C Y TEMPERATURA DE REFLUJO DEL SISTEMA DE SOLVENTE (60°C), TEMPERATURA DE REFLUJADO 70°C) Y ES DEJADA ENFRIARSE HASTA UNA SEGUNDA TEMPERATURA (0°C A 20°C) SIN DEJAR DE MANTENER UN GRADIENTE DE ENFRIAMIENTO CONTROLADO, SIENDO PREFERIBLEMENTE LA VELOCIDAD DE ENFRIAMIENTO DE 0,2°C/min A 0,4°C/min, LUEGO SE REALIZA EL SEMBRADO DE CRISTALES DE OXALATO DE ESCITALOPRAM EN DICHA SOLUCION DURANTE EL ENFRIAMIENTO SEGUIDO DE UN TIEMPO DE PERMANENCIA (4 A 24 HORAS) A DICHA SEGUNDA TEMPERATURA (0°C A 20°C), PARA LUEGO SEPARAR LOS CRISTALES, SIENDO LA RELACION PONDERAL ENTRE EL SOLUTO Y SOLVENTE DE 0,05 A 1. EL COMPUESTO ES INHIBIDOR DE ABSORCION DE SEROTONINA (5-HIDROXITRIPTAMINA)
PE2002000675A 2001-07-31 2002-07-26 Composicion cristalina que contiene escitalopram PE20030304A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200101164 2001-07-31

Publications (1)

Publication Number Publication Date
PE20030304A1 true PE20030304A1 (es) 2003-03-27

Family

ID=8160647

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000675A PE20030304A1 (es) 2001-07-31 2002-07-26 Composicion cristalina que contiene escitalopram

Country Status (39)

Country Link
US (3) US6916941B2 (es)
EP (2) EP1414435B1 (es)
JP (4) JP2005525993A (es)
KR (1) KR20040028947A (es)
CN (2) CN1660074A (es)
AR (1) AR034898A1 (es)
AT (2) ATE352546T1 (es)
AU (1) AU2002355624B2 (es)
BG (1) BG108571A (es)
BR (1) BR0206164A (es)
CA (1) CA2451915C (es)
CO (1) CO5560540A2 (es)
CY (1) CY1106413T1 (es)
DE (2) DE60202615T2 (es)
DK (2) DK1522539T3 (es)
EA (1) EA006213B1 (es)
EG (1) EG24206A (es)
ES (2) ES2280892T3 (es)
HR (2) HRP20031073A2 (es)
HU (1) HUP0401946A2 (es)
IL (2) IL159326A0 (es)
IS (1) IS7077A (es)
MA (1) MA27349A1 (es)
ME (1) MEP2108A (es)
MX (1) MXPA04000849A (es)
MY (1) MY126238A (es)
NO (1) NO328346B1 (es)
NZ (1) NZ530157A (es)
PE (1) PE20030304A1 (es)
PL (1) PL366995A1 (es)
PT (2) PT1414435E (es)
RS (1) RS8304A (es)
SI (1) SI1414435T1 (es)
TN (1) TNSN04021A1 (es)
TR (1) TR200400189T2 (es)
UA (1) UA79930C2 (es)
UY (1) UY27404A1 (es)
WO (1) WO2003011278A1 (es)
ZA (1) ZA200309684B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2291129C (en) 1999-04-14 2002-10-22 H. Lundbeck A/S Method for the preparation of citalopram
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
AR034898A1 (es) * 2001-07-31 2004-03-24 Lundbeck & Co As H Composicion cristalina que contiene escitalopram
PE20040991A1 (es) 2002-08-12 2004-12-27 Lundbeck & Co As H Separacion de intermediarios para la preparacion de escitalopram
WO2004085416A1 (en) * 2003-03-24 2004-10-07 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
WO2005084643A1 (en) * 2004-03-05 2005-09-15 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
WO2006123243A2 (en) * 2005-05-20 2006-11-23 Aurobindo Pharma Limited Pharmaceutical dosage forms comprising escitalopram in form of granules
TWI347942B (en) * 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
WO2007027612A2 (en) * 2005-08-29 2007-03-08 Teva Pharmaceutical Industries Ltd. Solid particulate tadalafil having a bimodal particle size distribution
CA2625835A1 (en) 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
CA2672925A1 (en) 2006-10-20 2008-04-24 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
US20090048336A1 (en) * 2007-08-17 2009-02-19 Naveen Kumar Kolla Escitalopram oxalate powders
WO2009135646A2 (en) * 2008-05-05 2009-11-12 Farmaprojects, Sa Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
ITMI20120448A1 (it) * 2012-01-30 2013-07-31 Carthesia Sas Composizione liofilizzata di escitalopram ossalato per somministrazione sublinguale
ITMI20120106A1 (it) * 2012-01-30 2013-07-31 Carthesia S A S Pastiglie liofilizzate di escitalopram ossalato per somministrazione sublinguale
CN106397249A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种高稳定性lcz696结晶粉末及其制备方法
JP2018016569A (ja) * 2016-07-26 2018-02-01 株式会社トクヤマ （１ｓ）−１−［３−（ジメチルアミノ）プロピル］−１−（４−フルオロフェニル）−１，３−ジヒドロイソベンゾフラン−５−カルボニトリル蓚酸塩の製造方法
WO2018190294A1 (ja) * 2017-04-10 2018-10-18 東和薬品株式会社 エスシタロプラム医薬組成物
CN107441052A (zh) * 2017-06-21 2017-12-08 山东京卫制药有限公司 一种含有草酸艾司西酞普兰的片剂及其制备方法
KR102089737B1 (ko) 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
JP7453859B2 (ja) * 2020-06-22 2024-03-21 東和薬品株式会社 エスシタロプラム錠剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (es) 1965-03-18
GB1358915A (en) 1971-09-13 1974-07-03 Merck & Co Inc Directly compressed tablet and composition therefor
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
DE3688827T2 (de) 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5296507A (en) 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
GB9325644D0 (en) 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5683720A (en) 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
AU5966196A (en) 1995-06-08 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
ATE205824T1 (de) 1997-07-08 2001-10-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
GB9714841D0 (en) 1997-07-14 1997-09-17 Smithkline Beecham Plc Treatment method
US5840334A (en) 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US5980941A (en) 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
UA62985C2 (en) 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
BR9714925A (pt) 1997-11-11 2003-07-22 Lundbeck & Co As H Método para preparação de citalopran, composto e composição farmacêutica antidepressiva
BR9915158B1 (pt) 1998-10-20 2012-02-22 método para preparação de citalopram, e, compostos da fórmula geral viii, ix e iv, ou qualquer de seus enantiÈmeros e sais com adição de ácido do mesmo.
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
CA2291129C (en) 1999-04-14 2002-10-22 H. Lundbeck A/S Method for the preparation of citalopram
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
WO2001022941A1 (en) * 1999-09-28 2001-04-05 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
GB2357762B (en) 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US6977306B2 (en) 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
AR034898A1 (es) 2001-07-31 2004-03-24 Lundbeck & Co As H Composicion cristalina que contiene escitalopram

Also Published As

Publication number Publication date
ATE286730T1 (de) 2005-01-15
IS7077A (is) 2003-12-15
DK1414435T3 (da) 2005-05-09
US20080305164A1 (en) 2008-12-11
DE60217932T2 (de) 2007-08-30
US7420069B2 (en) 2008-09-02
RS8304A (sr) 2006-12-15
BG108571A (en) 2005-02-28
AR034898A1 (es) 2004-03-24
NZ530157A (en) 2007-06-29
PL366995A1 (en) 2005-02-07
MEP2108A (xx) 2010-02-10
JP4971477B2 (ja) 2012-07-11
AU2002355624B2 (en) 2006-02-02
DE60202615T2 (de) 2006-01-12
CN1311819C (zh) 2007-04-25
IL159326A0 (en) 2004-06-01
JP5192568B2 (ja) 2013-05-08
JP2005525993A (ja) 2005-09-02
JP2012211186A (ja) 2012-11-01
DK1522539T3 (da) 2007-05-07
ZA200309684B (en) 2004-12-22
CA2451915A1 (en) 2003-02-13
HRPK20080410B3 (en) 2009-09-30
JP5719811B2 (ja) 2015-05-20
MXPA04000849A (es) 2004-05-14
HK1070000A1 (en) 2005-06-10
CY1106413T1 (el) 2011-10-12
KR20040028947A (ko) 2004-04-03
EP1414435B1 (en) 2005-01-12
DE60202615D1 (de) 2005-02-17
EG24206A (en) 2008-10-21
SI1414435T1 (en) 2005-06-30
CO5560540A2 (es) 2005-09-30
HUP0401946A2 (hu) 2005-01-28
HRP20080410A2 (en) 2008-10-31
PT1522539E (pt) 2007-03-30
NO20040380L (no) 2004-01-28
EP1414435A1 (en) 2004-05-06
CA2451915C (en) 2010-09-21
IL159326A (en) 2010-05-31
JP2010150283A (ja) 2010-07-08
NO328346B1 (no) 2010-02-01
TR200400189T2 (tr) 2004-12-21
JP2011195591A (ja) 2011-10-06
MY126238A (en) 2006-09-29
WO2003011278A1 (en) 2003-02-13
TNSN04021A1 (en) 2006-06-01
US6916941B2 (en) 2005-07-12
ATE352546T1 (de) 2007-02-15
CN1536997A (zh) 2004-10-13
US20030212128A1 (en) 2003-11-13
EP1522539B1 (en) 2007-01-24
ES2280892T3 (es) 2007-09-16
PT1414435E (pt) 2005-05-31
UA79930C2 (en) 2007-08-10
US20050147674A1 (en) 2005-07-07
MA27349A1 (fr) 2005-06-01
DE60217932D1 (de) 2007-03-15
CN1660074A (zh) 2005-08-31
ES2233842T3 (es) 2005-06-16
HRP20031073A2 (en) 2004-04-30
EA200400243A1 (ru) 2004-06-24
EA006213B1 (ru) 2005-10-27
BR0206164A (pt) 2003-10-28
UY27404A1 (es) 2003-02-28
EP1522539A1 (en) 2005-04-13

Similar Documents

Publication Publication Date Title
PE20030304A1 (es) Composicion cristalina que contiene escitalopram
AR044981A1 (es) Combinacion de un inhibidor alosterico de metaloproteinasa de matriz 13 (mmp-13) y un ligando de un receptor alfa-2- delta
AR032353A1 (es) Compuestos derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal y su uso en la fabricacion de medicamentos y composicion farmaceutica que los contiene
JP2011517657A5 (es)
DK153390C (da) Analogifremgangsmaade til fremstilling af cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalen-amin-derivater i racemisk form eller som optisk aktive (1s)-enantiomere eller farmaceutisk acceptable syreadditionssalte deraf
JP2005507932A5 (es)
RU93033485A (ru) Производные индола, фармацевтическая композиция, способ лечения
US4929605A (en) Pharmaceutical composition for piperidinoalkanol derivatives
AR022820A1 (es) Compuestos derivados de piridopiranoacepinas, en forma de isomeros geometricos u opticos puros o de mezcla de tales isomeros, procedimiento para su preparacion, medicamento y composicion farmaceutica.
ES2542842T3 (es) Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer
RU2008152085A (ru) Препаративные формы с контролируемым высвобождением
JP2016515546A5 (es)
PE20091018A1 (es) Novedosos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo y composicion farmaceutica de los mismos para el tratamiento de la eyaculacion prematura
CO4900080A1 (es) Microesferas farmaceuticas de acido valproico para administracion oral
BRPI0613491A2 (pt) antagonistas de piperazina-piperidina e agonistas do receptor de 5-ht1a
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA
AR056014A1 (es) Compuesto 3-aminocarbazol, composicion farmaceutica que lo contiene y procedimiento para la preparacion del mismo
RU2005131872A (ru) Производные бензотиазола (варианты), фармацевтическая композиция для детекции отложений амилоида и способ их детекции у млекопитающего
AR040078A1 (es) Diaminotiazoles
AR041376A1 (es) Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia
KR970010054B1 (ko) 허혈성 뇌장해 치료제
SE7707689L (sv) 2-brom-6-fluor-n-2-imidazolidinylidenbensamin dess syraadditionssalter, lekemedel innehallande dessa och forfarande for framstellning derav
JP2006510632A5 (es)
RU2005127809A (ru) Трансдермальная терапевтическая система, пригодная для использования тепла с целью ускорения проникновения биологически активных веществ, и ее применение
CO5290257A1 (es) Nuevos derivados de fenilheteroalquilamina, procesos para su preparacion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed